« Samson College Aims to Prepare High Quality Healthcare Professionals for In Demand Careers | Main | Back-to-School Season Means Time for Moms and Dads to Make Exercise a Priority, Says USciences Prof »


Pharmacy Prof Explains Properties of New Pain Pill Approved by FDA

Hussar_DanielOn the heels of the U.S. Food and Drug Administration's approval of an oxycodone pill designed to deter abuse, pharmacy professor Daniel Hussar, PhD, at University of the Sciences in Philadelphia, was featured on KYW Newsradio to explain the drug's properties.

Web story: KYW Newsradio: New Oxycodone Pill Designed To Prevent Abuse

Click here to listen to the KYW Radio audio segment

Purdue Pharma's new drug Targiniq ER is an extended release tablet that combines oxycodone — the active ingredient in OxyContin — with the drug naloxone. FDA regulators approved the drug for daily, round-the-clock pain that does not respond to other medications.

If abusers crush these tablets for snorting or injecting, naloxone blocks the euphoric effects of oxycodone, making the drug more difficult to abuse. Naloxone is currently used to reverse the overdose effects of opioids and highly addictive painkilling drugs, including morphine, methadone, codeine and others.


TrackBack URL for this entry:

Listed below are links to weblogs that reference Pharmacy Prof Explains Properties of New Pain Pill Approved by FDA:


Feed You can follow this conversation by subscribing to the comment feed for this post.

Post a comment.

If you have a TypeKey or TypePad account, please Sign In.

© 2011 University of the Sciences in Philadelphia • 600 South 43rd Street • Philadelphia, PA 19104 • 215.596.8800